Headline calls it cancer's 'master switch.' The thread's correction: a real weakness in 20% of tumors (economist.com)
The genuine advance is that KRAS, considered untargetable for decades, is becoming addressable as biologics improve. A working engineer in the thread supplied the context the headline skipped: why this is a real, bounded step.
And the crowd brought earned fatigue. After years of cancer-breakthrough headlines that never shipped, one reader's whole review was three words: 'May have? It also may have not.'
Sign in to save